Can a simple cream soothe psoriasis itch? small trial hopes to find out
NCT ID NCT06800755
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study tested a moisturizing medical device called RL3020-DP0364 (Dexeryl) in 40 adults with stable mild plaque psoriasis, dry skin, and itching. Participants applied the cream to their whole body (except head) for about a month. The main goal was to see if it reduced itch intensity. The trial is finished, but results are not yet reported.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Dexeryl (RL3020-DP0364) moisturizing cream
- What this could lead to
- If it works, this cream could offer a simple, non-drug way to reduce itching and dryness in people with mild psoriasis.
- What could go wrong
- This is a small, completed trial with only 40 people, so results may not apply to everyone. It is a moisturizer, not a treatment for psoriasis itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Jul 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: * Subject with stable mild plaque psoriasis covering ≤ 10% BSA (Body Surface Area; excluding the head\*) * Subject whose plaque psoriasis has been diagnosed for at least 6 months before the inclusion visit * Subject with dry skin according to the investigator assessment * Subject with a pruritus intensity (on average over the previous 24 hours) ≥ 3 on a Numerical Rating Scale (NRS) between 0 and 10 (with 0 = no pruritus and 10 = worst imaginable pruritus) on the body\* * the head is not included in the evaluated area Exclusion criteria: Criteria related to the disease: * Subject with erythrodermic psoriasis, pustular psoriasis * Subject with palmoplantar keratoderma * Subject with any other aetiology of pruritus, not related to plaque psoriasis * Subject with history of allergy or intolerance to any of the tested product ingredients * Subject having any other dermatologic condition than psoriasis, or characteristics (like tattoo, wound…) on body liable to interfere with the study assessments * Subject having an acute, chronic or progressive disease or history of disease liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements Criteria related to treatments and/or products: * Biotherapy treatment in the 6 months prior to the inclusion visit or ongoing or planned to be started during the study * Other systemic treatment for psoriasis (acitretin, cyclosporine, methotrexate, apremilast...) in the 3 months prior to the inclusion visit or ongoing or planned to be started during the study * Phototherapy treatment in the 4 weeks prior to the inclusion visit or ongoing or planned to be started during the study * Any other systemic treatment incompatible with the study or liable to interfere with the study assessments according to the investigator, in the weeks prior to the inclusion visit, ongoing or planned to be started during the study * Topical treatment for psoriasis (corticosteroid, vitamin D analogs…) applied on the body\* in the 4 weeks prior to the inclusion visit or ongoing or planned to be started during the study * Topical product (including any moisturizer, emollient, keratolytic …) applied on the body\* in the 7 days prior to the inclusion visit or ongoing or planned to be started during the study * Any product applied on the body\* before the visit, the day of inclusion visit * Any other topical treatment or product applied on the body\* incompatible with the study or liable to interfere with the study assessments according to the investigator, in the weeks prior to the inclusion visit, ongoing or planned to be started during the study * the head is not included in the evaluated area
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dry skin are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dermscan Poland
Gdansk, Poland, 80288, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Can a daily cream rebuild the Skin's barrier? trial puts moisturizer to the test
- Can a Once-Daily moisturizer help psoriasis skin? patients put it to the test
- Can a fruit acid in tiny carriers rival steroid creams for psoriasis?
- Vitamin B3 supplement put to the test against psoriasis inflammation
- Can monthly selfies and symptom logs reveal how chronic skin diseases flare and settle?